Cargando…
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease
The therapeutic benefits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are derived from the graft-versus-leukemia (GvL) effects of the procedure. There is a strong association between the GvL effects and graft-versus-host disease (GvHD), a major life-threatening complication of a...
Autores principales: | Choi, Jaebok, Cooper, Matthew L., Staser, Karl, Ashami, Kidist, Vij, Kiran R., Wang, Bing, Marsala, Lynne, Niswonger, Jessica, Ritchey, Julie, Alahmari, Bader, Achilefu, Samuel, Tsunoda, Ikuo, Schroeder, Mark A., DiPersio, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168427/ https://www.ncbi.nlm.nih.gov/pubmed/29691471 http://dx.doi.org/10.1038/s41375-018-0123-z |
Ejemplares similares
-
Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018) -
Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014) -
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models
por: Abboud, Ramzi, et al.
Publicado: (2023) -
Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018) -
Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease
por: Abboud, Ramzi, et al.
Publicado: (2020)